Lipoprotein(a)- and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
- 1 July 2004
- journal article
- Published by Elsevier in Kidney International
- Vol. 66 (1) , 348-354
- https://doi.org/10.1111/j.1523-1755.2004.00737.x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein (a) levelsLipids, 2002
- Lipoprotein(a) and Coronary Heart DiseaseCirculation, 2000
- Simvastatin in nephrotic syndromeKidney International, 1999
- Lipoprotein(a) in Health and DiseaseCritical Reviews in Clinical Laboratory Sciences, 1996
- The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentrationHuman Genetics, 1992
- Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.Journal of Clinical Investigation, 1991
- Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteersAtherosclerosis, 1989
- HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.Circulation, 1989
- Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitorJournal of Molecular Medicine, 1988
- Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.Journal of Clinical Investigation, 1987